The Value of ctDNA on Chemotherapy Efficacy for mCRC
Not Applicable
Recruiting
- Conditions
- Circulating Tumor DNA
- Interventions
- Genetic: ct-DNA
- Registration Number
- NCT04555369
- Lead Sponsor
- Fudan University
- Brief Summary
The study is designed to evaluate the value of ctDNA in predicting the drug efficacy of chemotherapy for metastatic colorectal cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
aged ≥18 years with histologically or cytologically confirmed advanced colorectal adenocarcinoma Eastern Cooperative Oncology Group performance status of 0 to 2 life expectancy of ≥ 3 months at least one measurable metastatic lesion have adequate bone marrow, hepatic, and renal function
Read More
Exclusion Criteria
patients with previous chronic inflammatory bowel disease, chronic diarrhea or recurrent bowel obstruction patients with symptomatic brain metastases active clinical severe infection
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description ct-DNA ct-DNA The enrolled mCRC patients will perform ct-DNA testing to evaluate drug efficacy of chemotherapy, at the time of baseline and after the first cycle of chemotherapy.
- Primary Outcome Measures
Name Time Method Response rate 2 months the response rate predicted by ct-DNA
- Secondary Outcome Measures
Name Time Method Overall survival 2 months Progression free survival 2 months
Trial Locations
- Locations (1)
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, Shanghai, China